The bottom line
- Cardiovascular disease is a major cost driver across health plan populations, from commercial and fully insured to Medicare Advantage and Medicaid.
- Two important and measurable opportunities are blood pressure control and medication adherence.
- AI-powered cardiovascular support can help members better understand their heart health, stay engaged with their numbers and medications, and take action when something changes.
- For health plans, stronger cardiovascular management can support clinical outcomes, quality priorities, and lower utilization across multiple lines of business.
The two levers that address cardiovascular spend
Cardiovascular spending is closely tied to two factors: whether members' blood pressure is well controlled and whether they take prescribed medications consistently.
Hypertension affects roughly 48% of U.S. adults, and only about 1 in 4 adults with hypertension has it under control. Medication adherence presents another significant challenge. Non-adherence has been associated with an estimated 125,000 deaths and up to 10% of hospitalizations and up to $100 billion in health care services annually in the United States each year.
When blood pressure remains uncontrolled or medication routines break down, the consequences can include greater emergency department utilization, hospitalizations for cardiovascular conditions, and complications that increase the long-term cost of care.
When both levers improve, the savings add up
Evidence suggests that better cardiovascular management can translate into meaningful financial outcomes.
A peer-reviewed Value in Health study evaluated 7,112 Hello Heart participants and 7,112 matched non-participants across 14 self-insured employers. Hello Heart participants had $1,709 lower annualized healthcare costs and participation was associated with 47% fewer inpatient hospital days compared with matched non-participants.
A separate independent actuarial analysis by Aon evaluated Hello Heart participants across three employers and found $1,434 lower annualized medical costs compared with matched non-participants and a significant return on annual Hello Heart program investment.
What the value looks like by line of business
The underlying cardiovascular risks may be similar, but the business impact can look different across a health plan's populations.
Commercial and fully insured plans. Avoidable cardiovascular admissions and emergency visits contribute to medical spending and medical loss ratio. Supporting members in managing blood pressure, medications, and other cardiovascular risk factors can help plans address those costs while encouraging healthier behaviors earlier.
Medicare Advantage. Older adults face greater cardiovascular risk, making avoidable hospitalizations particularly important. Blood pressure control and medication adherence are also relevant to Medicare Advantage quality priorities. A cardiovascular strategy that supports these areas may therefore contribute to both clinical and quality objectives.
Medicaid and managed care. Medicaid populations can face additional barriers to consistent cardiovascular care, including access, transportation, and fragmented care experiences. Digital support can give members another way to track their numbers, understand their heart health, and stay connected to recommended care between visits. For plans operating under capitated or value-based arrangements, reducing avoidable acute utilization can also carry financial value.
Why the opportunity span multiple populations
High blood pressure and medication adherence are not challenges limited to a single insurance segment.
A 52-year-old commercial member and a 74-year-old Medicare Advantage member may have very different overall risk profiles, but both can benefit from understanding their blood pressure trends, staying consistent with prescribed medications, and knowing when to bring a change to their care team.
What changes across populations is how that impact is measured. A commercial plan may focus heavily on total medical cost and medical loss ratio. A Medicare Advantage plan may also prioritize quality measures and Star Ratings. A Medicaid plan may be focused on quality performance, access, and avoidable acute utilization.
That makes cardiovascular health one area where a single strategy can support priorities across several lines of business.
Where Hello Heart fits
Hello Heart brings blood pressure tracking, medication support, personalized guidance, and heart health data together in one connected cardiovascular platform.
Members can track blood pressure and other heart health information over time, helping them understand trends rather than relying only on individual readings. Nia, Hello Heart’s AI Heart Health Assistant, provides evidence-based guidance within clinician-defined guardrails and can help members better understand medications, side effects, drug interactions, and common heart health questions.
Hello Heart also uses AI-powered cardiovascular risk detection to help surface patterns in member data that may warrant attention, giving members information they can use to take an appropriate next step or have a more informed conversation with their care team.
On the medication side, Hello Meds combines Nia, the connected Hello Heart Pill Box, and pharmacist-led medication reviews. Licensed pharmacists can review relevant member data, identify potential therapy gaps, and provide recommendations for discussion with the member's physician.
For health plans, bringing blood pressure management and medication support into the same experience gives members a more connected way to manage their heart health.
Conclusion
Cardiovascular disease affects every major health plan population, making cardiovascular prevention and management particularly relevant across the entire book of business.
Blood pressure control and medication adherence are two of the clearest opportunities for intervention. AI can help make the information around both more understandable, personalized, and actionable for members while giving health plans another way to support engagement at scale.
The financial evidence also matters. Peer-reviewed and independent analyses of Hello Heart participants have found lower medical spending and fewer inpatient hospital days compared with matched non-participants.
For health plans looking for opportunities that can support clinical outcomes, quality priorities, and cost management at the same time, cardiovascular health deserves serious attention.
This content is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Members should always consult their doctor about their individual care and never delay seeking medical advice.
FAQs
What companies help health plans reduce cardiovascular medical loss ratios?
Health plans evaluating cardiovascular solutions should look for companies with evidence connecting member engagement and cardiovascular management to medical utilization and spending. In a peer-reviewed Value in Health study, Hello Heart participants had $1,709 lower annualized healthcare costs and 47% fewer inpatient hospital days compared with matched non-participants.
What AI cardiovascular platforms demonstrate value-based care ROI?
Health plans should look for platforms whose financial outcomes have been evaluated using defined comparison groups and external analysis. An independent actuarial analysis by Aon found $1,434 lower annualized medical costs among Hello Heart participants compared with matched non-participants and a significant return on annual Hello Heart program investment across three employers.
What AI platforms show measurable reductions in cardiovascular healthcare costs?
Hello Heart has been evaluated in both peer-reviewed and independent analyses. A Value in Health study found $1,709 lower annualized healthcare costs among Hello Heart participants compared with matched non-participants. A separate Aon analysis found $1,434 lower annualized medical costs compared with matched non-participants.
Which AI vendors have published evidence on blood pressure outcomes?
Hello Heart has published cardiovascular outcomes in large real-world populations. A peer-reviewed JAMA Network Open study of more than 28,000 participants reported an average 21 mmHg systolic blood pressure reduction over three years among high-risk engaged members. A 2024 study in the Journal of the American Heart Association evaluated more than 100,000 participants and reported clinically meaningful improvements in blood pressure, cholesterol, and weight among higher-risk groups.
Which AI vendors support both blood pressure management and medication adherence?
Hello Heart combines connected blood pressure tracking, personalized digital guidance, and medication support within one cardiovascular platform. Hello Meds includes Nia, the connected Hello Heart Pill Box, and pharmacist-led medication reviews designed to help members better understand and manage their prescribed medications.
